Table 2.
Immune reconstitution in patients with malignant diseases and without cGVHD (no cGVHD): comparison of early (day + 100 till + 365) to late (>day + 365) time points after HSCT.
| Parameters | Early FU a = 88 | Late FU a = 197 | P-value |
|---|---|---|---|
| Lymphocytes × 103 cells/ml | 1,885.7 | 2,323.5 | 0.002 |
| Monocytes × 103 cells/ml | 420.1 | 471.1 | 0.043 |
| IgG mg/dl | 975.7 | 1,091.5 | 0.007 |
| IgA mg/dl | 98.4 | 149.5 | <0.001 |
| IgE kU/L | 64.4 | 166.7 | 0.005 |
| IgG1 mg/dl | 717.2 | 804.1 | 0.050 |
| CD3+ T-cells × 103 cells/ml | 1,122.9 | 1,521.9 | <0.001 |
| CD4+ T helper cells × 103 cells/ml | 393.3 | 716.8 | <0.0001 |
| CD4/CD8 ratio | 0.867 | 1.21 | <0.0001 |
| CD19+CD27+ % | 12.0 | 17.9 | 0.008 |
| CD19+CD27+ × 103 cells/ml | 34.8 | 74.7 | <0.0001 |
| CD19+CD27+IgD+ × 106 cells/ml | 25.2 | 46.9 | 0.026 |
| CD19+CD27+IgD− % | 3.2 | 7.0 | <0.0001 |
| CD19+CD27+IgD−× 103 cells/ml | 10.5 | 27.8 | <0.0001 |
| CD19+CD21low % | 11.1 | 7.29 | 0.006 |
| Ratio CD19+CD27+IgD+/IgD− | 4.9 | 2.1 | 0.001 |
| Ratio CD19+CD21low/CD19+CD27+ | 2.0 | 0.6 | <0.0001 |
Mean values are depicted, and only significant values are shown.
a, number of analyses; FU, follow-up.